National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Tisagenlecleucel (Kymriah®) which is licensed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 19/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/10/2018
Pre-submission consultation with Applicant 06/11/2018
Submission received from Applicant 23/01/2019
Preliminary review sent to Applicant 28/05/2019
Current status Awaiting response from Applicant